Medicus Pharma (MDCX) vs Nasus Pharma (NSRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nasus Pharma (NSRX) has outperformed Medicus Pharma (MDCX) over the past year, losing 50.1% versus a loss of 95.9%. Nasus Pharma is the larger company by market cap ($42.5 million vs $7.3 million), about 5.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDCX | NSRX |
|---|---|---|
| Share price | $0.1019 | $3.63 |
| Market cap | $7.31M | $42.52M |
| 1-day change | -36.39% | -3.84% |
| YTD return | -93.34% | -60.33% |
| 1-year return | -95.86% | -50.07% |
| EPS (TTM) | $-2.38 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.78 | $9.50 |
| 52-week low | $0.0941 | $1.98 |
| Distance from 52-week high | -96.33% | -61.79% |
| Analyst consensus | none | buy |
| Avg. price target upside | +4316.09% | +441.87% |
| Average volume | 4.43M | 16.09K |
| Shares outstanding | 71.71M | 11.71M |
| Employees | 16 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nasus Pharma is about 5.8 times larger than Medicus Pharma by market value ($42.52M vs $7.31M).
- NSRX has outperformed MDCX by 45.8 percentage points over the past year.
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Healthcare · Drug Manufacturers - General · 16 employees
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Healthcare · Drug Manufacturers - General · 7 employees
MDCX vs NSRX FAQ
Which is bigger, Medicus Pharma or Nasus Pharma?
Nasus Pharma (NSRX) is larger, with a market capitalization of $42.52M compared with $7.31M for Medicus Pharma (MDCX).
Which stock has performed better over the past year, MDCX or NSRX?
NSRX returned -50.07% over the past 12 months, compared with -95.86% for MDCX (price return, excluding dividends). Past performance does not predict future results.
Are Medicus Pharma and Nasus Pharma in the same industry?
Yes. Both are classified in the Drug Manufacturers - General industry within the Healthcare sector.